Sign in
Taking people in South AfricaNo phase

Testing Genetic Sequencing to Guide Treatment for Drug-resistant Tuberculosis

Tests a genetic sequencing test to guide treatment in people with drug-resistant tuberculosis.

Key facts

Who runs it
University of California, San Francisco
Where
Cape Town, South AfricaSee the site
Trial code
Registry title
Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis
Status
Recruiting
People taking part
2,500 people, planned
Started
1 Aug 2024
Expected to end
Jan 2027
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Targeted next-generation sequencing
Record updated
26 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people diagnosed with active rifampin-resistant tuberculosis at a study facility, with a positive TB test from a sample.

Sex
Anyone can join, men and women.
Disease stage
Active rifampin-resistant tuberculosis (RR-TB) diagnosed at a study facility during the study period.
Biomarker or test result
A positive Mtb culture, smear, or sample derivative (for example a GenoLyse remnant or Xpert cartridge extract).

Main reasons for not taking part

  • Expects to move out of the study region
  • Does not agree to take part in the study
  • Later found to have rifamycin susceptibility on at least two additional tests

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Active RR-TB diagnosed at a study facility during the study period
  • Positive Mtb culture, smear, or specimen derivative (e.g., GenoLyse remnant, Xpert cartridge extract)

Who cannot take part

  • Patient expects to relocate/move residence outside of the study region
  • Patient does not agree to participate in the study; In addition, participants later found to have isolates with rifamycin susceptibility on at least two additional tests (e.g., phenotypic DST, LPA, or sequencing) will be considered late exclusions

This trial is currently available in South Africa.

  • South African National Health Laboratory ServiceCape Town, South AfricaContact: Robin M Warren, PhDTaking people

About the trial

What the trial wants to find out

TS ELiOT is a stepped-wedge, cluster randomized trial assessing the effect of a next-generation sequencing-based strategy on rifampin-resistant tuberculosis management and patient outcomes.

The 2 groups in the trial

  • Sequencing Intervention in addition to standard of careTreatment being tested

    Batched targeted deep sequencing in addition to the locally accepted standard of care drug susceptibility determination of multidrug/extensively drug-resistant tuberculosis (M/XDR-TB)

    Treatment: Targeted next-generation sequencing

  • Standard of CareNo study treatment, for comparison

    Locally accepted standard of care which is consistent with the WHO recommendations for the drug susceptibility determination of M/XDR-TB

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Targeted Sequencing to Enhance, Liberate, and Optimize Treatment of Drug-resistant Tuberculosis
Plain-language title
Testing Genetic Sequencing to Guide Treatment for Drug-resistant TuberculosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
26 January 2026